JP2023548945A5 - - Google Patents

Info

Publication number
JP2023548945A5
JP2023548945A5 JP2023528750A JP2023528750A JP2023548945A5 JP 2023548945 A5 JP2023548945 A5 JP 2023548945A5 JP 2023528750 A JP2023528750 A JP 2023528750A JP 2023528750 A JP2023528750 A JP 2023528750A JP 2023548945 A5 JP2023548945 A5 JP 2023548945A5
Authority
JP
Japan
Prior art keywords
fusion protein
seq
polypeptide
amino acid
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023528750A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023548945A (ja
Filing date
Publication date
Priority claimed from PCT/CN2020/129067 external-priority patent/WO2022099695A1/en
Application filed filed Critical
Publication of JP2023548945A publication Critical patent/JP2023548945A/ja
Publication of JP2023548945A5 publication Critical patent/JP2023548945A5/ja
Pending legal-status Critical Current

Links

JP2023528750A 2020-11-16 2021-11-08 Cd164融合タンパク質およびその適用 Pending JP2023548945A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CNPCT/CN2020/129067 2020-11-16
PCT/CN2020/129067 WO2022099695A1 (en) 2020-11-16 2020-11-16 Cd164 fusion and uses thereof
PCT/CN2021/129378 WO2022100555A1 (en) 2020-11-16 2021-11-08 Cd164 fusion and uses thereof

Publications (2)

Publication Number Publication Date
JP2023548945A JP2023548945A (ja) 2023-11-21
JP2023548945A5 true JP2023548945A5 (cg-RX-API-DMAC10.html) 2024-09-19

Family

ID=81600756

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023528750A Pending JP2023548945A (ja) 2020-11-16 2021-11-08 Cd164融合タンパク質およびその適用

Country Status (5)

Country Link
US (1) US20240002469A1 (cg-RX-API-DMAC10.html)
EP (1) EP4244260A4 (cg-RX-API-DMAC10.html)
JP (1) JP2023548945A (cg-RX-API-DMAC10.html)
CN (4) CN115947871A (cg-RX-API-DMAC10.html)
WO (2) WO2022099695A1 (cg-RX-API-DMAC10.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022099695A1 (en) * 2020-11-16 2022-05-19 Jiangsu Cell Tech Medical Research Institute Co., Ltd. Cd164 fusion and uses thereof
CN116609531B (zh) * 2023-05-23 2025-10-31 哈尔滨医科大学 Mydgf在治疗血管内模增生的制药和医疗器械中的应用
WO2025047991A1 (en) * 2023-09-01 2025-03-06 Boehringer Ingelheim International Gmbh Myeloid-derived growth factor for use in treating or preventing a liver disorder
CN119798458B (zh) * 2024-12-05 2025-09-26 河南大学 一种dr5和mydgf的融合蛋白及其应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040162236A1 (en) * 2002-04-01 2004-08-19 John Alsobrook Therapeutic polypeptides, nucleic acids encoding same, and methods of use
AR045074A1 (es) * 2003-07-23 2005-10-12 Applied Research Systems Uso de cd164 soluble en desordenes inflamatorios y autoinmunes
US7803910B2 (en) * 2005-01-24 2010-09-28 Merck Serono S.A. Soluble CD164 polypeptides
US9156897B2 (en) * 2012-06-08 2015-10-13 Alkermes, Inc. Fusion polypeptides comprising an active protein linked to a mucin-domain polypeptide
EP2941438A1 (en) * 2013-01-01 2015-11-11 Kahr Medical Ltd. Stable form of signal converting protein fusion proteins, and methods of use and preparation thereof
PT2945642T (pt) * 2013-01-17 2024-05-27 Medizinische Hochschule Hannover Proteína do fator 1 para utilização no tratamento ou prevenção de doenças
EP3157558A2 (en) * 2014-06-23 2017-04-26 Immunomic Therapeutics, Inc. Nucleic acids for treatment of peanut allergies
MX2017004947A (es) * 2014-10-24 2017-06-29 Bristol Myers Squibb Co Polipeptidos del factor de crecimiento de fibroblastos 2 (fgf-21) modificados y usos de los mismos.
EP3612556B8 (en) * 2017-04-22 2024-11-20 Immunomic Therapeutics, Inc. Improved lamp constructs
CN111544572B (zh) * 2020-05-15 2022-06-07 中山大学 Mydgf蛋白在制备端粒酶表达和细胞衰老调控剂中的应用
WO2022099695A1 (en) * 2020-11-16 2022-05-19 Jiangsu Cell Tech Medical Research Institute Co., Ltd. Cd164 fusion and uses thereof

Similar Documents

Publication Publication Date Title
KR102927838B1 (ko) 이중 작용 단백질 및 이를 포함하는 약학적 조성물
US11858975B2 (en) Multi-domain active protein for treating metabolic diseases
JP2025114622A (ja) 融合タンパク質を含む、肝炎、肝線維症、および肝硬変を予防または処置するための医薬組成物
JP6412183B2 (ja) 作用持続時間が増した改変ポリペプチド
JP5373855B2 (ja) 選択可能な特性を有するハイブリッドポリペプチド
CN105008395B (zh) 长效单链胰岛素类似物
CN109310641A (zh) 用于受控和持续释放的elp融合蛋白
KR20170049319A (ko) 지속형 fgf21 융합 단백질 및 이를 포함하는 약학적 조성물
CN103370083A (zh) 具有增强的作用持续时间的工程化多肽
CA3151351A1 (en) Compositions and particles for payload delivery
US10815286B2 (en) Fusion protein for treating intestinal diseases
CN115003702A (zh) Cd164融合蛋白及其应用
CN111234015B (zh) 用于延长药物半衰期的抗体、其融合蛋白和应用
WO2023280133A1 (zh) 融合蛋白及其应用
CN118076373A (zh) 用于联合疗法的包括生长分化因子-15变体和胰高血糖素样肽-1受体激动剂的组合物
JP2023509189A5 (cg-RX-API-DMAC10.html)
RU2795548C2 (ru) Фармацевтическая композиция для предотвращения или лечения гепатита, фиброза печени и цирроза печени, включающая слитые белки
HK40091844A (en) Dual function proteins and pharmaceutical composition comprising same
HK40086042A (en) Dual function proteins and pharmaceutical composition comprising same
JPWO2009005000A1 (ja) ペプチド性薬物の粘膜吸収促進剤を含有する粘膜投与用組成物、及びその投与方法
HK40012348B (en) Pharmaceutical composition for preventing or treating hepatitis, hepatic fibrosis, and hepatic cirrhosis comprising fusion proteins
RU2023111124A (ru) Фармацевтическая композиция для предотвращения или лечения гепатита, фиброза печени и цирроза печени, включающая слитые белки
HK40012348A (en) Pharmaceutical composition for preventing or treating hepatitis, hepatic fibrosis, and hepatic cirrhosis comprising fusion proteins